(Q46588982)

23 December 2017

title

Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers (English)

1 reference

23 December 2017

severe acute respiratory syndrome

1 reference

1 reference

Hsueh-Erh Chiou

1

1 reference

23 December 2017

Ching-Lung Liu

2

1 reference

23 December 2017

Mary Jeanne Buttrey

3

1 reference

23 December 2017

Han-Pin Kuo

4

1 reference

23 December 2017

Hui-Wen Liu

5

1 reference

23 December 2017

Hsu-Tah Kuo

6

1 reference

23 December 2017

Yen-Ta Lu

7

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

published in

Chest

1 reference

23 December 2017

volume

128

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

263-272

1 reference

23 December 2017

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

cites work

1 reference

12 December 2020

Managing SARS amidst uncertainty

1 reference

12 December 2020

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

12 December 2020

Sequential symptomatic analysis in probable severe acute respiratory syndrome cases

1 reference

12 December 2020

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

1 reference

12 December 2020

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

1 reference

12 December 2020

Early goal-directed therapy in the treatment of severe sepsis and septic shock

1 reference

12 December 2020

Treatment of SARS with human interferons.

1 reference

12 December 2020

Hepatitis C: natural history, diagnosis, and management.

1 reference

12 December 2020

Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection

1 reference

12 December 2020

Oral ribavirin treatment of influenza A and B.

1 reference

12 December 2020

The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital

1 reference

12 December 2020

Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada

1 reference

12 December 2020

SARS: pharmacotherapy

1 reference

12 December 2020

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

1 reference

12 December 2020

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

1 reference

12 December 2020

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

1 reference

12 December 2020

Personal view of SARS: confusing definition, confusing diagnoses.

1 reference

12 December 2020

Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever

1 reference

12 December 2020

Antiviral treatment of SARS: can we draw any conclusions?

1 reference

12 December 2020

Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.

1 reference

12 December 2020

Aminopeptidase N inhibitors and SARS

1 reference

12 December 2020

Hemorrhagic fever viruses as biological weapons: medical and public health management

1 reference

12 December 2020

Impact of treatment guidelines on use of ribavirin.

1 reference

12 December 2020

The severe acute respiratory syndrome

1 reference

12 December 2020

Development of a standard treatment protocol for severe acute respiratory syndrome

1 reference

12 December 2020

Ribavirin in the treatment of SARS: A new trick for an old drug?

1 reference

12 December 2020

Identifiers

DOI

10.1378/CHEST.128.1.263

1 reference

23 December 2017

1 reference

23 December 2017